Acute Ischemic Stroke. occlusion and stenosis of cerebral and precerebral arteries, resulting in cerebral infarction
Conditions
Interventions
Intervention 1: Routine treatment for Acute Ischemic Stroke (based on ward protocol) plus Daily infusion of IMOD (Herbal extract of Tanacetum Vulgare, Rosa Canina and Urtica dioica enriched with Selen
Treatment - Drugs
Routine treatment for Acute Ischemic Stroke (based on ward protocol) plus Daily infusion of IMOD (Herbal extract of Tanacetum Vulgare, Rosa Canina and Urtica dioica enriched with Selenium, 120 mg/4cc)
Routine treatment for Acute Ischemic Stroke (based on ward protocol)
Sponsors
Vice Chancellor for Research, Tabriz University of Medical Sciences
Pars Roos Co.
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: all patients with acute ischemic stroke (based on clinical and imaging findings) Exclusion criteria: age less than 18years or more than 80 years, prior neurological deficit of any cause, cancer or any other severe disease, rapidly improving symptoms prior to intervention, NIHSS less than 5 at disease presentation, symptom onset less than 3 hours or more than 24 hours, no informed consent, concurrent immunosuppressive / immunomodulator drug use.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neurological outcome of Acute Ischemic Stroke. Timepoint: Prior to intervention, days 7 & 90 after symptom onset. Method of measurement: National Institute of Health Stroke Scale (NIHSS).;Functional outcome of Acute Ischemic Stroke. Timepoint: Prior to intervention, days 7 & 90 after symptom onset. Method of measurement: Modified Rankin Scale (MRS).;Arm Motor deficit following Acute Ischemic Stroke. Timepoint: Prior to intervention, days 7 & 90 after symptom onset. Method of measurement: National Institute of Health Stroke Scale (NIHSS).;Sensory deficit following Acute Ischemic Stroke. Timepoint: Prior to intervention, days 7 & 90 after symptom onset. Method of measurement: National Institute of Health Stroke Scale (NIHSS).;Facial palsy following Acute Ischemic Stroke. Timepoint: Prior to intervention, days 7 & 90 after symptom onset. Method of measurement: National Institute of Health Stroke Scale (NIHSS).;Leg Motor deficit following Acute Ischemic Stroke. Timepoint: Prior to intervention, days 7 & 90 after symptom onset. Method of measurement: National Institute of Health Stroke Scale (NIHSS).;Best Language following Acute Ischemic Stroke. Timepoint: Prior to intervention, days 7 & 90 after symptom onset. Method of measurement: National Institute of Health Stroke Scale (NIHSS).;Dysarthria following Acute Ischemic Stroke. Timepoint: Prior to intervention, days 7 & 90 after symptom onset. Method of measurement: National Institute of Health Stroke Scale (NIHSS). | — |
Secondary
| Measure | Time frame |
|---|---|
| IL-1. Timepoint: Prior to intervention and days 4 & 7 after symptom onset. Method of measurement: ELISA.;IL-6. Timepoint: Prior to intervention and days 4 & 7 after symptom onset. Method of measurement: ELISA.;Relative Frequency of Hemorrhagic Complications. Timepoint: 7th day after symptom onset. Method of measurement: Spiral Brain CT scan.;Relative Frequency of Infectious Complications. Timepoint: 7th day after symptom onset. Method of measurement: Blood Culture; Urine Culture; CXRay alterations.;Survival. Timepoint: 90th day after symptom onset. Method of measurement: Kaplan-Meier survival curves.;TNF-alpha. Timepoint: Prior to intervention and days 4 & 7 after symptom onset. Method of measurement: ELISA.;WBC. Timepoint: Prior to intervention and days 4 & 7 after symptom onset. Method of measurement: Cell count.;Platelet. Timepoint: Prior to intervention and days 4 & 7 after symptom onset. Method of measurement: Cell count. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mehdi Farhoudi
Neuroscience Research Center, Tabriz University of Medical Sciences
Outcome results
None listed